Ventricular tachycardia cardiac MRI: Difference between revisions

Jump to navigation Jump to search
 
(27 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Ventricular tachycardia}}
{{Ventricular tachycardia}}
{{CMG}} ; {{AE}} {{Sara.Zand}} {{ADG}}
==Overview==
When [[structural heart disease]] is suspected in the context of [[ventricular tachycardia]], it is necessary to have an accurate evaluation of the structure and function of the [[atria]] and [[ventricle]]s.  While [[echocardiography]] is the first modality of choice, [[MRI]] is used when the assessment provided by [[echocardiography]] is not satisfactory.  In addition, [[MRI]] seems to have an important role in the evaluation of suspected [[arrhythmogenic right ventricular cardiomyopathy]] because [[MRI]] provides a good assessment of the [[RV|right ventricular]] structure, function, and fatty infiltration if present.
== [[Cardiac MRI]]==
* [[ Cardiac MRI]] is an accurate modality for evaluation of  the precursor of [[ventricular arrhythmia]], or [[SCD]] including [[ischemic heart disease]], [[myocarditis]], [[cardiomyopathic]] process based on the following:<ref name="ColemanShaw2017">{{cite journal|last1=Coleman|first1=G. Cameron|last2=Shaw|first2=Peter W.|last3=Balfour|first3=Pelbreton C.|last4=Gonzalez|first4=Jorge A.|last5=Kramer|first5=Christopher M.|last6=Patel|first6=Amit R.|last7=Salerno|first7=Michael|title=Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis|journal=JACC: Cardiovascular Imaging|volume=10|issue=4|year=2017|pages=411–420|issn=1936878X|doi=10.1016/j.jcmg.2016.05.009}}</ref>
# Quantification of [[LVEF]], [[left ventricular]] mass, and [[volume]]
#  Anomaly of [[coronary arteries]] origin
# [[Valvular heart disease]]
# [[Myocardial scar]]
# [[Infiltrative process]] by late [[gadolinium]] enhancement
# [[LV]] , [[RV]] function
# Degree of fibrosis in [[LV]], [[RV]] in [[HCM]] and [[ ARVC]]
*[[Cardiac magnetic resonance imaging]] can be especially helpful in the evaluation of uncommon [[myocardial]] infiltrative diseases, such as [[sarcoidosis]].<ref name="pmid16443541">{{cite journal| author=Kiès P, Bootsma M, Bax J, Schalij MJ, van der Wall EE| title=Arrhythmogenic right ventricular dysplasia/cardiomyopathy: screening, diagnosis, and treatment. | journal=Heart Rhythm | year= 2006 | volume= 3 | issue= 2 | pages= 225-34 | pmid=16443541 | doi=10.1016/j.hrthm.2005.10.018 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16443541  }} </ref>
*[[MRI]] can be useful in [[patients]] with [[ventricular tachycardia]] when [[echocardiography]] fails to provide accurate evaluation of [[Left ventricle|left]] or [[right ventricular]] function.


Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
== 2017 AHA/ACC/HRS Guidelines for Management of [[Patients]] With [[Ventricular Arrhythmia]]s==
==Overview==
When structural heart disease is suspected in the context of ventricular tachycardia, it is necessary to have an accurate evaluation of the structure and function of the [[atria]] and [[ventricle]]s.  While [[echocardiography]] is the first modality of choice, [[MRI]] is used when the assessment provided by echocardiography is not satisfactory.  In addition, [[MRI]] seems to have an important role in the evaluation of suspected [[arrythmogenic right ventricular cardiomyopathy]] because [[MRI]] provides a good assessment of the right ventricular structure, function and fatty infiltrate if present.


== 2006 ACC/AHA/ESC Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT) <ref name="pmid16935995">{{cite journal| author=Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al.| title=ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. | journal=Circulation | year= 2006 | volume= 114 | issue= 10 | pages= e385-484 | pmid=16935995 | doi=10.1161/CIRCULATIONAHA.106.178233 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16935995}}</ref> ==


=== Left Ventricular Function and Imaging (DO NOT EDIT) <ref name="pmid16935995">{{cite journal| author=Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al.| title=ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. | journal=Circulation | year= 2006 | volume= 114 | issue= 10 | pages= e385-484 | pmid=16935995 | doi=10.1161/CIRCULATIONAHA.106.178233 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16935995}}</ref> ===


{| class="wikitable"
{| class="wikitable"
Line 14: Line 28:
| Colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| Colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
|-
| Bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[MRI]], [[cardiac]] [[computed tomography]] ([[CT]]), or [[radionuclide angiography]] can be useful in patients with [[ventricular arrhythmias]] when [[echocardiography]] does not provide accurate assessment of [[LV]] and [[RV]] function and/or evaluation of structural changes.'' ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence B]])<nowiki>"</nowiki>''
| Bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1''' [[ Cardiac MRI]] or [[cardiac]] [[computed tomography]] ([[CT]]), can be useful in [[patients]] with [[ventricular arrhythmias]] when [[structural heart disease]] is considered.'' ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence C]])<nowiki>"</nowiki>''
|-
| Bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' [[LV]] imaging can be useful in patients undergoing biventricular pacing. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence C]])<nowiki>"</nowiki>''
|}
|}


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


 
[[Category:Cardiology]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Electrophysiology]]
[[Category:Cardiology]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Intensive care medicine]]
[[Category:Needs content]]
[[Category:Radiology]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]
[[Category:Up-To-Date cardiology]]
[[Category:Up-To-Date]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 05:16, 13 September 2022

Ventricular tachycardia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ventricular Tachycardia from other Disorders

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography

Cardiac MRI

Other Diagnostic Tests

Treatment

Medical Therapy

Electrical Cardioversion

Ablation

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ventricular tachycardia cardiac MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ventricular tachycardia cardiac MRI

CDC onVentricular tachycardia cardiac MRI

Ventricular tachycardia cardiac MRI in the news

Blogs on Ventricular tachycardia cardiac MRI

to Hospitals Treating Ventricular tachycardia cardiac MRI

Risk calculators and risk factors for Ventricular tachycardia cardiac MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2] Aditya Ganti M.B.B.S. [3]

Overview

When structural heart disease is suspected in the context of ventricular tachycardia, it is necessary to have an accurate evaluation of the structure and function of the atria and ventricles. While echocardiography is the first modality of choice, MRI is used when the assessment provided by echocardiography is not satisfactory. In addition, MRI seems to have an important role in the evaluation of suspected arrhythmogenic right ventricular cardiomyopathy because MRI provides a good assessment of the right ventricular structure, function, and fatty infiltration if present.

Cardiac MRI

  1. Quantification of LVEF, left ventricular mass, and volume
  2. Anomaly of coronary arteries origin
  3. Valvular heart disease
  4. Myocardial scar
  5. Infiltrative process by late gadolinium enhancement
  6. LV , RV function
  7. Degree of fibrosis in LV, RV in HCM and ARVC


2017 AHA/ACC/HRS Guidelines for Management of Patients With Ventricular Arrhythmias

Class IIa
"1 Cardiac MRI or cardiac computed tomography (CT), can be useful in patients with ventricular arrhythmias when structural heart disease is considered. (Level of Evidence C)"

References

  1. Coleman, G. Cameron; Shaw, Peter W.; Balfour, Pelbreton C.; Gonzalez, Jorge A.; Kramer, Christopher M.; Patel, Amit R.; Salerno, Michael (2017). "Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis". JACC: Cardiovascular Imaging. 10 (4): 411–420. doi:10.1016/j.jcmg.2016.05.009. ISSN 1936-878X.
  2. Kiès P, Bootsma M, Bax J, Schalij MJ, van der Wall EE (2006). "Arrhythmogenic right ventricular dysplasia/cardiomyopathy: screening, diagnosis, and treatment". Heart Rhythm. 3 (2): 225–34. doi:10.1016/j.hrthm.2005.10.018. PMID 16443541.

Template:WH Template:WS